Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02338843 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3 study, sponsored by La Jolla Pharmaceutical Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 344
- Enrollment target
NCT02338843: Completed Phase 3 study, sponsored by La Jolla Pharmaceutical Company.
NCT02338843 is a Phase 3 study that has completed, run by La Jolla Pharmaceutical Company. The registered enrollment target is 344 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02338843, a Phase 3 study, has completed, sponsored by La Jolla Pharmaceutical Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 344 participants
- Enrollment target
Study Summary
This is a Phase 3, double-blind, randomized study of LJPC-501 (angiotensin II) in adult patients diagnosed with catecholamine-resistant hypotension (CRH) conducted in multiple centers globally.
Primary Outcome
Response with respect to mean arterial pressure (MAP) at hour 3 after the start of infusion was defined as an increase from baseline of at least 10 mm Hg or an increase to at least 75 mm Hg, without an increase in the dose of background vasopressors.
Interventions
- DRUG Placebo
- DRUG LJPC-501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-02-18 |
| Phase | Phase 3 |
What the finished NCT02338843 record still lists
NCT02338843 is an interventional study that assigns participants to a tested intervention. The registered 344 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02338843 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02338843 about?
NCT02338843 is a clinical study titled "A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension". This is a Phase 3, double-blind, randomized study of LJPC-501 (angiotensin II) in adult patients diagnosed with catecholamine-resistant hypotension (CRH) conducted in multiple centers globally.
What is the current status of trial NCT02338843?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 344 participants. The study started on 2015-03. Estimated completion is 2017-02-18.
What interventions are being tested in trial NCT02338843?
The interventions under investigation include: Placebo (DRUG), LJPC-501 (DRUG).
Who is sponsoring clinical trial NCT02338843?
This trial is sponsored by La Jolla Pharmaceutical Company, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02338843's enrollment target sits among peer trials
344 1050th of 2000 higher than 950 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06733363 · 344 participants · Phase 2
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
- NCT07179380 · 344 participants · Phase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- NCT07304024 · 344 participants · Phase 1
A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
- NCT03972657 · 345 participants · Phase 1
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia